Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female between, and including, 42 and 69 days of age at the time of the first vaccination.~* Born after a gestation period of 37 to 42 weeks inclusive.~* Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.~* Written informed consent obtained from the parent(s)/ Legally Acceptable Representative(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.~* Administration of a vaccine not foreseen by the study protocol, within 30 days prior to the first study visit, with the exception of hepatitis B and Bacillus Calmette-Guérin vaccination; or planned administration during the study period, with the exception of hepatitis B and influenza vaccines, which will be allowed at least 7 days before or 30 days after the administration of the DTPa vaccine.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis and Hib vaccination or disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Family history of congenital or hereditary immunodeficiency.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).~* Major congenital defects or serious chronic illness.~* History of any neurological disorders or seizures.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Acute disease and/or fever at the time of enrolment.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 69 Days
- Healthy Volunteers: t

Study Arms:
- Infanrix-IPV+Hib Group (Type: EXPERIMENTAL): Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
- Infanrix IPV Group (Type: ACTIVE_COMPARATOR): Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).